scholarly journals Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial

2012 ◽  
Vol 108 (8) ◽  
pp. 1443-1454 ◽  
Author(s):  
Suzanne J. Meldrum ◽  
Nina D'Vaz ◽  
Karen Simmer ◽  
Janet A. Dunstan ◽  
Kathryn Hird ◽  
...  
Keyword(s):  
Fish Oil ◽  
Child Behavior Checklist ◽  
Controlled Trial ◽  
Small Subset ◽  
High Dose ◽  
Neurodevelopmental Outcomes ◽  
Pufa Supplementation ◽  
Pufa Intake ◽  
Communicative Development ◽  
Significant Difference

n-3 Long-chain PUFA (LC-PUFA) intake during infancy is important for neurodevelopment; however, previous studies of n-3 LC-PUFA supplementation have been inconclusive possibly due to an insufficient dose and limited methods of assessment. The present study aimed to evaluate the effects of direct supplementation with high-dose fish oil (FO) on infant neurodevelopmental outcomes and language. In the present randomised, double-blind, placebo-controlled trial, 420 healthy term infants were assigned to receive a DHA-enriched FO supplement (containing at least 250 mg DHA/d and 60 mg EPA/d) or a placebo (olive oil) from birth to 6 months. Assessment occurred at 18 months via the Bayley Scales of Infant and Toddler Development (3rd edition; BSID-III) and the Child Behavior Checklist. Language assessment occurred at 12 and 18 months via the Macarthur–Bates Communicative Development Inventory. The FO group had significantly higher erythrocyte DHA (P = 0·03) and plasma phospholipid DHA (P = 0·01) levels at 6 months of age relative to placebo. In a small subset analysis (about 40 % of the total population), children in the FO group had significantly higher percentile ranks of both later developing gestures at 12 and 18 months (P = 0·007; P = 0·002, respectively) and the total number of gestures (P = 0·023; P = 0·006, respectively). There was no significant difference between the groups in the standard or composite scores of the BSID-III. The results suggest that improved postnatal n-3 LC-PUFA intake in the first 6 months of life using high-dose infant FO supplementation was not beneficial to global infant neurodevelopment. However, some indication of benefits to early communicative development was observed.

Abstract 134: Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Downstream n-3 Fatty Acid Metabolites in Patients With Peripheral Artery Disease

2014 ◽  
Vol 34 (suppl_1) ◽  
Author(s):  
Marlene Grenon ◽  
Christopher Owens ◽  
Hugh Alley ◽  
Karen Chong ◽  
Priscilla Yen ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Fatty Acid ◽  
Fish Oil ◽  
Short Duration ◽  
Peripheral Artery Disease ◽  
High Dose ◽  
Peripheral Artery ◽  
Pufa Supplementation ◽  
Fish Group ◽  
Artery Disease

OBJECTIVES: Patients with peripheral artery disease (PAD) experience significant morbidity and mortality, at least partially related to vascular inflammation and endothelial dysfunction. The OMEGA-PAD I Trial (NCT01310270), a randomized, double-blinded, placebo-controlled trial addressed the hypothesis that short-duration, high-dose n-3 polyunsaturated fatty acids (n-3 PUFA) oral supplementation improves endothelial function (EF) and inflammation in subjects with PAD. METHODS: Eighty patients with stable, mild-severe claudication and ABI<0.9 received 4.1gm of fish oil (FISH) vs placebo capsules (CTL) for 1 month. The primary endpoint was EF as measured by brachial artery flow-mediated vasodilation (FMD). Secondary endpoints included biomarkers of inflammation, generation of n-3 fatty acid-derived lipid metabolites, lipid profile and walking impairment questionnaires. RESULTS: The FISH and CTL group were no different with regards to age, baseline EF, inflammation and lipid profiles. Following treatment, there was a significant reduction in triglycerides (-34 ± 46, p=0.0001) and an improvement in HDL (+2 ± 6, p=0.03) in the FISH group. These changes were accompanied by an increase in the omega-3 index of 4 ± 1% (p<0.00001). We observed a significant increase in the production of downstream metabolites of n-3 fatty acids including 18-, 15- and 5-hydroxy eicosapentaenoic acids and 4-hydroxy docosahexaenoic acid in the FISH group. n-3 PUFA led to a significant improvement in FMD in the FISH group (+0.7 ± 4.0%, p=0.04) and a non-significant improvement in the CTL (+0.6 ± 2.5, p=0.18) group. There were no significant differences between groups in pro-inflammatory markers or walking parameters post-treatment. CONCLUSIONS: High-dose, short-duration n-3 PUFA supplementation significantly improves the metabolo-lipidomic profile of patients with PAD. Longer studies are needed to assess the effects of n-3 PUFA on inflammation, vascular function, and clinical endpoints in patients with established PAD and to determine whether generation of n-3 fatty acid-derived bioactive lipid mediators is related to clinical outcomes.

High-Dose Nadroparin Following Endovascular Aneurysm Treatment Benefits Outcome After Aneurysmal Subarachnoid Hemorrhage

Neurosurgery ◽  
2017 ◽  
Vol 83 (2) ◽  
pp. 281-287 ◽  
Author(s):  
Rene Post ◽  
IJsbrand A.J Zijlstra ◽  
Rene van den Berg ◽  
Bert A Coert ◽  
Dagmar Verbaan ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Dose Group ◽  
Low Dose ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Controlled Trial ◽  
Delayed Cerebral Ischemia ◽  
Neurological Status ◽  
High Dose ◽  
Aneurysm Treatment ◽  
Significant Difference

Abstract BACKGROUND Delayed cerebral ischemia (DCI) is one of the major causes of delayed morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). OBJECTIVE To evaluate the effect of high-dose nadroparin treatment following endovascular aneurysm treatment on the occurrence of DCI and clinical outcome. METHODS Medical records of 158 adult patients with an aSAH were retrospectively analyzed. Those patients treated endovascularly for their ruptured aneurysm were included in this study. They received either high-dose (twice daily 5700 AxaIE) or low-dose (once daily 2850 AxaIE) nadroparin treatment after occlusion of the aneurysm. Medical charts were reviewed and imaging was scored by 2 independent neuroradiologists. Data with respect to in-hospital complications, peri-procedural complications, discharge location, and mortality were collected. RESULTS Ninety-three patients had received high-dose nadroparin, and 65 patients prophylactic low-dose nadroparin. There was no significant difference in clinical DCI occurrence between patients treated with high-dose (34%) and low-dose (31%) nadroparin. More patients were discharged to home in patients who received high-dose nadroparin (40%) compared to low-dose (17%; odds ratio [OR] 3.13, 95% confidence interval [95% CI]: 1.36-7.24). Furthermore, mortality was lower in the high-dose group (5%) compared to the low-dose group (23%; OR 0.19, 95% CI: 0.07-0.55), also after adjusting for neurological status on admission (OR 0.21, 95% CI: 0.07-0.63). CONCLUSION Patients who were treated with high-dose nadroparin after endovascular treatment for aneurysmal SAH were more often discharged to home and showed lower mortality. High-dose nadroparin did not, however, show a decrease in the occurrence of clinical DCI after aSAH. A randomized controlled trial seems warranted.

scholarly journals Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use

2013 ◽  
Vol 74 (1) ◽  
pp. 89-95 ◽  
Author(s):  
Susanna M Proudman ◽  
Michael J James ◽  
Llewellyn D Spargo ◽  
Robert G Metcalf ◽  
Thomas R Sullivan ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Fish Oil ◽  
Low Dose ◽  
Controlled Trial ◽  
Smoking History ◽  
Treat To Target ◽  
Control Group ◽  
High Dose ◽  
Dmard Therapy ◽  
Early Ra

BackgroundThe effects of fish oil (FO) in rheumatoid arthritis (RA) have not been examined in the context of contemporary treatment of early RA. This study examined the effects of high versus low dose FO in early RA employing a ‘treat-to-target’ protocol of combination disease-modifying anti-rheumatic drugs (DMARDs).MethodsPatients with RA <12 months’ duration and who were DMARD-naïve were enrolled and randomised 2:1 to FO at a high dose or low dose (for masking). These groups, designated FO and control, were given 5.5 or 0.4 g/day, respectively, of the omega-3 fats, eicosapentaenoic acid + docosahexaenoic acid. All patients received methotrexate (MTX), sulphasalazine and hydroxychloroquine, and DMARD doses were adjusted according to an algorithm taking disease activity and toxicity into account. DAS28-erythrocyte sedimentation rate, modified Health Assessment Questionnaire (mHAQ) and remission were assessed three monthly. The primary outcome measure was failure of triple DMARD therapy.ResultsIn the FO group, failure of triple DMARD therapy was lower (HR=0.28 (95% CI 0.12 to 0.63; p=0.002) unadjusted and 0.24 (95% CI 0.10 to 0.54; p=0.0006) following adjustment for smoking history, shared epitope and baseline anti–cyclic citrullinated peptide. The rate of first American College of Rheumatology (ACR) remission was significantly greater in the FO compared with the control group (HRs=2.17 (95% CI 1.07 to 4.42; p=0.03) unadjusted and 2.09 (95% CI 1.02 to 4.30; p=0.04) adjusted). There were no differences between groups in MTX dose, DAS28 or mHAQ scores, or adverse events.ConclusionsFO was associated with benefits additional to those achieved by combination ‘treat-to-target’ DMARDs with similar MTX use. These included reduced triple DMARD failure and a higher rate of ACR remission.

scholarly journals Effects of Industrial Waste Fish Oil Administration on Interleukin-6 (Il-6) Expression at Mice Colon being Induced by Azoxymethane (AOM) and Dextran Sodium Sulphate (DSS)

2021 ◽  
Vol 14 (4) ◽  
pp. 2227-2233
Author(s):  
Kevin Tjoa ◽  
Kusmardi Kusmardi ◽  
Yurnadi Hanafi Midoen
Keyword(s):  
Fish Oil ◽  
Industrial Waste ◽  
Positive Control ◽  
Negative Control ◽  
High Dose ◽  
Omega 3 ◽  
Colon Tissue ◽  
Significant Difference ◽  
Solvent Control ◽  
Medium Dose

Colorectal cancer (CRC) is the world’s third most cancer and the second highest mortality rate. The searching for new anti-inflammation substances with less adverse effects than aspirin for chemoprevention and adjuvant chemotherapy of CRC is running. The most notable one is fish oil containing omega 3. Kusmardi, et al. studied that industrial waste fish oil omega-3 level comes close enough to conventional fish oil industry. Study aims to reducing the level IL-6 on mice colon tissue being induced CRC using AOM/DSS by fish oil administration. Thirty male Swiss Webster mice are grouped into six treatments: positive control (aspirin), negative control (physiological saline), normal, high dose (fish oil 6mg/kgBW), medium dose (fish oil 3mg/kgBW), dan solvent control (corn oil). Colon tissue was stained using anti IL-6 antibody. Ten photos per slide were taken by microscope (400x), analyzed for the IL-6 expression by ImageJ®, and quantified for H-score. Data was analyzed using SPSS 24.0 (CI 95%) and p-value <0.05 is consider significant. Data are not normally distributed with median of 161.64 (119.4-260.67). Kruskal-Wallis test is significant in addition with Mann-Whitney test shows only high dose group has significant difference to negative control (p=0.008), medium dose (p=0.016) dan and solvent control (p=0.008). No significant difference reported between high dose and positive control group (p=0.69). High dose industrial waste fish oil can lower IL-6 expression in mice colon tissue induced CRC using AOM/DSS.

Neurodevelopmental Outcomes of Preterm Infants Treated with Oral Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus

2017 ◽  
Vol 34 (12) ◽  
pp. 1185-1189 ◽  
Author(s):  
Zeynep Eras ◽  
Nurdan Uras ◽  
Fuat Canpolat ◽  
Omer Erdeve ◽  
Serife Oguz ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Preterm Infants ◽  
Infant Development ◽  
Controlled Trial ◽  
Ductus Arteriosus ◽  
Neurodevelopmental Outcomes ◽  
Significant Difference ◽  
Oral Ibuprofen ◽  
Patent Ductus

Objective This study aims to determine the effects of paracetamol versus ibuprofen treatment given to preterm infants for the pharmacological closure of patent ductus arteriosus (PDA) on neurodevelopmental outcomes at 18 to 24 months' corrected age. Method A follow-up study was conducted to evaluate the neurodevelopmental outcomes of preterm infants (gestational age ≤ 30 weeks) enrolled in a randomized controlled trial comparing oral paracetamol versus oral ibuprofen for the closure of PDA. The developmental assessment was done by using “Bayley Scales of Infant Development, Second Edition” at 18 to 24 months' corrected age. Results A total of 80 infants completed the trial protocol. Of the 75 infants eligible for follow-up, 61 infants (30 in the paracetamol group and 31 in the ibuprofen group) were evaluated. There was no significant difference in neurodevelopmental outcomes between the two groups. Conclusion The neurodevelopmental outcomes did not differ among the preterm infants who receive either paracetamol or ibuprofen at 18 to 24 months' corrected age.

scholarly journals Blood DHA, Choline, and Lutein Concentrations and Their Correlation with Cognitive and Behavioral Outcomes in 18-Month Old Toddlers: Preliminary Findings

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1065-1065
Author(s):  
Larissa Rossen ◽  
Sarah Montgomery ◽  
Deborah Zibrik ◽  
Roger Dyer ◽  
Tim Oberlander ◽  
...  
Keyword(s):  
British Columbia ◽  
Effortful Control ◽  
Child Behavior Checklist ◽  
Infant Development ◽  
System Development ◽  
Short Form ◽  
Controlled Trial ◽  
Nervous System Development ◽  
Neurodevelopmental Outcomes ◽  
Cross Sectional

Abstract Objectives The objective of this study was to investigate associations between key nutrients identified as critical for central nervous system development and function, but which are limited in the diet of toddlers, and neurodevelopmental outcomes in toddler-aged children. We hypothesize that higher concentrations of key nutrients are associated with higher neurocognitive development scores. Methods Cross-sectional baseline data were drawn from 18-month old toddlers residing in Vancouver, Canada, who participated in a partially randomized controlled trial investigating associations between feeding patterns, nutrient biomarker status, and neurodevelopmental outcomes. Cognitive and behavioural outcomes considered for this analysis included: The Bayley Scale of Infant Development (3rd Ed; BSID-III); Child Behavior Checklist (CBCL); Early Childhood Behavior Questionnaire Very Short Form (ECBQ); and the MacArthur-Bates Communicative Development Inventories (Words & Gestures and Words & Sentences; MCDI-WG & WS). Blood biomarkers of nutrients of interest included plasma concentration of ferritin, lutein, choline, vitamins A and D, and betaine, as well as docosahexaenoic acid (DHA) measured as a percentage of total fatty acids in red blood cells. Results Sixty-nine toddlers (34 boys, 35 girls) with preliminary data available had a mean gestational age at birth and birthweight of 39.5 weeks and 3.48 kg, respectively. Preliminary (unadjusted) findings show higher levels of DHA corresponded with lower scores of effortful control on the ECBQ (rho = –.35, P &lt; .01) while higher levels of lutein were associated with higher scores on the MCDI-WG (rho = .33, P &lt; .05). Conclusions These preliminary findings may reflect an important association between nutritional status and optimal brain function at 18-months of age, a period of life which is particularly sensitive to nutrient inadequacies. These findings require confirmation in a larger sample size and causality testing of the relationship in a dose-dependency trial. Funding Sources This study is supported by The University of British Columbia, and the British Columbia Children's Hospital Research Institute, Canada, and is funded by Société des Produits Nestlé S.A.

scholarly journals Effect of Intravenous High Dose Vitamin C on Postoperative Pain and Morphine Use after Laparoscopic Colectomy: A Randomized Controlled Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Younghoon Jeon ◽  
Jun Seok Park ◽  
Suyoung Moon ◽  
Jinseok Yeo
Keyword(s):  
Postoperative Pain ◽  
Vitamin C ◽  
Laparoscopic Colectomy ◽  
Controlled Trial ◽  
Plasma Concentrations ◽  
Antioxidant Properties ◽  
Morphine Consumption ◽  
High Dose ◽  
Significant Difference ◽  
High Dose Vitamin

Background and Objective. Vitamin C has antioxidant, neuroprotective, and neuromodulating effects. Recently, it showed antinociceptive effect as a result of the antioxidant properties. Therefore, we designed this study to assess the effect of intravenous vitamin C on opiate consumption and pain in patients undergoing laparoscopic colectomy.Methods. A total of 100 patients were enrolled and allocated to receive 50 mg/kg vitamin C or placebo by intravenous infusion immediately after induction of anesthesia. Morphine consumption and scores of pain were assessed at 2, 6, and 24 h after completion of surgery.Results. There were 97 patients included in the analysis. Patients who received vitamin C had higher plasma concentrations of vitamin C at the end of surgery, significantly lower morphine consumption at the 2 h after end of surgery, and significantly lower pain scores at rest during first 24 h postoperatively. There was no significant difference between groups in side effects, fatigue score, or pain score during cough.Conclusion. This study shows high dose vitamin C infusion decreased postoperative pain during the first 24 h and reduced morphine consumption in the early postoperative period. Additional research needed to examine whether higher doses of vitamin C and longer infusion times can amplify these effects.

Sign in / Sign up

Export Citation Format

Share Document